Incidence, Characteristics and Evolution of Cerebral Vasospasm with Clinical Impact in Moderate to Severe Traumatic Brain Injury Complicated by Subarachnoid Hemorrhage At Martinique University Hospital (VASO-TC)

March 26, 2025 updated by: University Hospital Center of Martinique

Context :

Moderate to severe head trauma with altered state of consciousness is an extremely common pathology (between 60 and 120 cases per 100 000 people per year depending on the country and age group), and is responsible for 30% of deaths by trauma. It is complicated in 30-60% of cases by subarachnoid hemorrhage (SAH), which makes it the leading cause of SAH. SAH and its complications are well described when the origin is aneurysmal, notably cerebral vasospasm (CV) because it promotes delayed cerebral ischemia with a major prognostic impact. This is why the screening and prevention of this vasospasm are well established in the literature and in practice, in the nosological context of aneurysmal SAH.

Research problem :

However, when it comes to post-traumatic SAH, CV is a more maligned entity, with a much less detailed description. However, when we know the prognostic interest that it could have for patients, it seems legitimate to seek to define its physiopathological and epidemiological contours. On a prospective cohort of 290 subjects, Oertel et al. (2005) demonstrated, in head trauma patients, an incidence of approximately 40% of compatible signs with the recognized criteria of CV.

To date, the literature remains sparse on this subject.

Proposed study :

In view of the incomplete scientific literature, the study team wish to carry out a prospective epidemiological study in moderate to severe head trauma patients complicated by SAH and hospitalized at the Martinique University Hospital, with the aim of better characterizing the incidence of the occurrence, and evolution of CV with clinical impact in these patients.

One of the original aspects of the proposed study is the use of CT scan with perfusion sequence, which has shown its superiority to Transcranial Doppler. The other particularity is its prospective aspect and triggered by an alteration in the clinical state of the patient presenting a traumatic SAH, then directly linking the pathophysiology (cerebral ischemia) and the clinical impact. Thus, the diagnosis of traumatic CV will be made on a cerebral CT scan by the association of the 50% reduction in the caliber of one or more cerebral arteries and a perfusion defect in the perfusion sequence in a context of alteration of neurological clinical examination or deterioration of neurological monitoring parameters. Finally, few studies have monitored the evolution of these patients at 1 and 6 months after the initial event.

Hypothesis :

The research hypothesis is that in the population of moderate to severe head trauma patients hospitalized at the Martinique University Hospital, when a new neurological symptomatology or a deterioration in the state of consciousness occurs, it could be a post-truamatic CV in 15 to 20% of cases.

Indeed, the rare studies find frequencies of radiologically confirmed CV in head trauma patients of around 30-45%, with low numbers of subjects, retrospective studies, or not correlated with the clinic and with the clinical and paraclinical data necessary for the positive diagnosis of this entity. The reported frequency of traumatic CV with clinical impact ranges between 15-20%.

The study team therefore expect an incidence of 15 to 20% of CV with clinical impact in patients with traumatic SAH in Martinique. CV could be responsible for sudden deterioration of the neurological state in patients suffering from traumatic SAH between the 3rd and 12th day inclusive of treatment (according to retrospective studies already carried out) and responsible for its specific morbidity linked to cerebral ischemia localized in the spasmed area manifested by a worsening of the neurological prognosis on the modified Rankin scale.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

154

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Fort-de-France, France, 97261
        • Recruiting
        • University Hospital Center of Martinique
        • Contact:
        • Contact:
          • Marie SABIA, PhD
        • Contact:
          • Christina IOSIF, PhD
        • Contact:
          • Hossein MEHDAOUI, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Adult patient aged 18 or over,
  • Hospitalized at the Martinique University Hospital for the treatment or monitoring of a moderate or severe TBI (Glasgow Score less than or equal to 13 at initial treatment) presenting with SAH on the cerebral CT scan,
  • Patient if capable, or representative of the patient in case of incapacity, having been informed of the research, and having given free, informed and written consent,
  • After an emergency inclusion procedure if the patient's representative is initially unreachable and written agreement, informed within the first 48 hours of inclusion by the representative or the patient if his neurological condition allows it,
  • Be affiliated to a social security system.

Exclusion Criteria:

  • Pregnant woman,
  • Presence of an aneurysmal pathology known or diagnosed at initial treatment,
  • History of chronic kidney failure stage 4 (creatinine clearance measured less than 30ml/min),
  • Imminent death of the patient,
  • Patient presenting criteria for non-admission to critical care (death expected within 48 hours, progressive fatal pathology with vital prognosis in less than 30 days, patient in palliative situation),
  • Known allergy to iodized contrast products,
  • Be placed under legal protection, guardianship or curatorship,
  • Patient or representative who refused to allow the patient to participate in the study.

Additional Exclusion Criteria after patient's inclusion:

  • Death of the patient expected within the first 48 hours,
  • Minor,
  • Release from hospitalization against medical advice,
  • Transfer to another establishment before the 13th day of treatment (outside the Martinique University Hospital),
  • Change of opinion of the patient's representative (after neurological recovery) regarding the patient's participation in research,
  • Withdrawal of consent to participate in the study being supported with refusal to use the data collected until withdrawal of participation,

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Treatment or monitoring of a moderate or severe TBI presenting with SAH on initial cerebral CT scan

Patients hospitalized at Martinique University Hospital for treatment or monitoring of a moderate or severe TBI (Glasgow Score less than or equal to 13 at initial treatment) presenting with SAH on initial cerebral CT scan.

Any head trauma patient with an altered level of consciousness must benefit, as part of routine care, from clinical monitoring and a CT imaging assessment, as well as the opinion of the doctor on duty in the resuscitation department.

If the patient has a traumatic SAH on the cerebral CT scan, he must benefit from an injected sequence exploring the supra-aortic trunks. If there is evidence of intracranial hypertension on cerebral CT or abnormal transcranial doppler, they will benefit, according to the service protocol, from the placement of a parenchymal intracranial pressure sensor. These patients also benefit from clinical monitoring in critical care, as well as a daily biological assessment.

Neurological monitoring by daily TCD will be carried out.

  • If monitoring finds, between 3rd and 12th day of treatment, a neurological deterioration or an uncontrolled increase in intracranial pressure, a new cerebral CT scan will be performed, as recommended in such a case.
  • As part of this research, a specific interventional act will be implemented: additional brain perfusion scan sequence which would allow the radiological diagnosis of CV.
  • Interventions related to improving cerebral perfusion and reducing intracranial pressure recommended in head trauma patients will be implemented without modification of management linked to protocol.

The additional perfusion sequences will be analyzed independently and blindly by 2 experienced interventional neuroradiologists (double reading blinded to the patient's characteristics).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Estimate the incidence of cerebral vasospasm (CV) with clinical impact in moderate to severeTBI patients complicated by subarachnoid hemorrhage (SAH) at Martinique University Hospital.
Time Frame: 42 months

Number of incident cases of post-traumatic CV with cerebral perfusion defect observed in the event of new symptoms or neurological worsening in moderate to severe TBI between 3rd and 12th day of treatment post-traumatic in critical care during the study period.

Incidence will be calculated by reporting the number of incident cases of traumatic CV over the total number of patients at risk (traumatic SAH) observed during the study period.

42 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Describe the characteristics of traumatic CV diagnosed in the study sample.
Time Frame: 42 months
Characteristics of post-traumatic CV diagnosed in the study sample: topography (affected cerebral artery and impacted brain area)
42 months
Describe the characteristics of traumatic CV diagnosed in the study sample.
Time Frame: 42 months
Characteristics of post-traumatic CV diagnosed in the study sample: time to onset
42 months
Describe the characteristics of traumatic CV diagnosed in the study sample.
Time Frame: 42 months
Characteristics of post-traumatic CV diagnosed in the study sample: time to possible recurrences
42 months
Describe the characteristics of traumatic CV diagnosed in the study sample.
Time Frame: 42 months
Characteristics of post-traumatic CV diagnosed in the study sample: duration of each CV episode
42 months
Analyze the risk factors for the occurrence of traumatic CV.
Time Frame: 42 months

Supposed risk factors for post-traumatic CV described in the scientific literature:

  • SAH intensity (Fisher and WFNS Score, VASOGRADE Score),
  • State of consciousness at treatment (Glasgow Coma Scale at treatment),
  • Pre-existing high blood pressure,
  • Tobacco consumption,
  • Left ventricular hypertrophy,
  • Age,
  • Sex.

The association between the presence of these factors and the occurrence of post-traumatic CV will be quantified by measures of association (odds ratio) resulting from the implementation of appropriate modeling techniques (logistic regression).

42 months
Compare the neurological morbidity at 30 days and 6 months of patients with and without post-traumatic CV in the study sample.
Time Frame: 42 months

Neurological morbidity: Modified Rankin score at 1 month and 6 months after initial treatment.

The modified Rankin Score is a disability scale used in the long-term assessment of disability linked to acute neurological pathologies (scale ranging from 0-autonomy to 6-death).

Neurological morbidity at 1 and 6 months will be compared between patients with and without post-traumatic CV in the study sample.

42 months
Analyze the association between the worsening of the neurological prognosis 6 months after initial patient management, and the presence of a traumatic CV.
Time Frame: 42 months
The association between the presence of post-traumatic CV and the worsening of the neurological prognosis (Rankin Score ≥ 4) will be quantified by the association measures (odds-ratio) resulting from the implementation of modeling techniques adequate (logistic regression).
42 months
Assess quality of life at 6 months
Time Frame: 42 months
Level of quality of life at 6 months after initial treatment, assessed by the McGill questionnaire for measuring patients quality of life (McGill Quality of Life Questionnaire, revised version, MQOL-R).
42 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Marie SABIA, PhD, University Hospital Center of Martinique

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 6, 2024

Primary Completion (Estimated)

November 6, 2028

Study Completion (Estimated)

December 6, 2028

Study Registration Dates

First Submitted

July 23, 2024

First Submitted That Met QC Criteria

August 14, 2024

First Posted (Actual)

August 19, 2024

Study Record Updates

Last Update Posted (Actual)

March 31, 2025

Last Update Submitted That Met QC Criteria

March 26, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cerebral Vasospasm

Subscribe